



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Cwm Taf Morgannwg  
University Health Board



## Freedom of Information Request: Our Reference CTMUHB\_03\_25

### You asked:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

### Our response:

Please see provided below as requested a table populated with the information Medicines Management are able to provide at this current time. The period the data relates to is 1<sup>st</sup> October 24 to 31<sup>st</sup> December 24 the latest 3 months available.

| Medicine               | Number of Patients |
|------------------------|--------------------|
| Abatacept [Orencia]    | 52                 |
| Adalimumab [Humira]    | 35                 |
| Adalimumab Biosimilars | 374                |
| Apremilast [Otezla]    | 24                 |

|                          |     |
|--------------------------|-----|
| Baricitinib [Olumiant]   | 32  |
| Bimekizumab [Bimzelx]    | 13  |
| Certolizumab [Cimzia]    | 57  |
| Etanercept [Enbrel]      | 22  |
| Etanercept Biosimilars   | 215 |
| Filgotinib [Jyseleca]    | 8   |
| Golimumab [Simponi]      | 43  |
| Guselkumab [Tremfya]     | **  |
| Infliximab [Remicade]    | **  |
| Infliximab Biosimilars   | 17  |
| Ixekizumab [Taltz]       | 18  |
| Risankizumab [Skyrizi]   | 0   |
| Rituximab [MabThera]     | **  |
| Rituximab Biosimilars    | 28  |
| Sarilumab [Kevzara]      | **  |
| Secukinumab [Cosentyx]   | 83  |
| Tocilizumab [Ro Actemra] | 68  |
| Tocilizumab Biosimilars  | **  |
| Tofacitinib [Xeljanz]    | 7   |
| Upadacitinib [Rinvoq]    | 26  |
| Ustekinumab [Stelara]    | 15  |
| Ustekinumab Biosimilar   | **  |

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.